- Home
- Apac Medication Assisted Mat Treatment Market
APAC Medication Assisted (MAT) Treatment Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-382 | No of pages: 273 | Format:
The Asia-Pacific medication-assisted treatment (MAT) market is projected to register a substantial CAGR of 10.5% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2019, the base year of calculation is 2021, and the forecast period is 2022 to 2029.
Market Segmentation:
Asia-Pacific Medication-Assisted Treatment (MAT) Market, By Type (Medication and Therapy), Products (Buprenorphine and Naloxone, Naltrexone, Buprenorphine, Methadone, Naloxone, Disulfiram, and Acamprosate), Drug Type (Generics and Branded), Dosage Form (Immediate Release and Extended Release), Route of Administration (Oral, Parenteral, and Others), Population Type (Adults and Teenage), End User (Rehabilitation Clinics, Hospitals, Specialty Centres, Homecare, and Others) Distribution Channel (Hospital Pharmacy, Direct Tender, Retail Pharmacy, Online Pharmacy, and Others), Country (China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of Asia-Pacific medication-assisted treatment (MAT) are:
The rise in incidence of alcohol use disorder and opioid use disorders
Increasing awareness of MAT
Market Players:
Some of the major players operating in the Asia-Pacific medication-assisted treatment (MAT) market are:
Indivior PLC
Sun Pharmaceutical Industries Ltd.
Taj Pharmaceuticals Limited
Hikma Pharmaceuticals PLC
Pfizer Inc.
Glenmark Pharmaceutical Inc.
Viatris Inc.
Alvogen
Accord Healthcare
Teva Pharmaceutical Industries Ltd.
Dr. Reddys Laboratories Ltd.
Amneal Pharmaceuticals LLC. among others
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 49
1.1 OBJECTIVES OF THE STUDY 49
1.2 MARKET DEFINITION 49
1.3 OVERVIEW OF ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET 49
1.4 CURRENCY AND PRICING 52
1.5 LIMITATIONS 52
1.6 MARKETS COVERED 53
2 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SEGMENTATION 57
2.1 MARKETS COVERED 57
2.2 GEOGRAPHICAL SCOPE 58
2.3 YEARS CONSIDERED FOR THE STUDY 59
2.4 DBMR TRIPOD DATA VALIDATION MODEL 60
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 63
2.6 MULTIVARIATE MODELLING 64
2.7 PRODUCT SEGMENT LIFELINE CURVE 64
2.8 DBMR MARKET POSITION GRID 65
2.9 VENDOR SHARE ANALYSIS 67
2.10 MARKET END USER COVERAGE GRID 68
2.11 SECONDARY SOURCES 69
3 EXECUTIVE SUMMARY 70
4 PREMIUM INSIGHTS 74
4.1 EPIDEMIOLOGY 75
4.2 PESTEL 76
4.3 PORTER'S FIVE FORCES MODEL 77
4.4 ANNUAL INCIDENCE OF SUBJECTS ENTERING MEDICATION-ASSISTED TREATMENT IN ALCOHOL, OPIOID USE DISORDER, AND OPIOID OVERDOSE PREVENTION (2021) 78
4.5 ANNUAL NUMBER OF TREATMENTS WITH CLONIDINE AND WITH LOFEXIDINE IN OPIOID USE DISORDER AND OPIOID OVERDOSE PREVENTION (2021) 78
4.6 ANNUAL INCIDENCE OF INDIVIDUALS RE-ENTERING MEDICATION-ASSISTED TREATMENT. FOR EXAMPLE, SOMEONE MAY DROP OUT OF TREATMENT AND RESTART TREATMENT LATER (2021) 79
4.7 ANNUAL USE OF NALTREXONE INJECTION AS PART OF TREATMENT FOR THE INITIAL WITHDRAWAL FROM OPIOIDS, AND ANNUAL MAINTENANCE THERAPY USING NALTREXONE INJECTION (2021) 79
4.8 PIPELINE ANALYSIS FOR MEDICATION-ASSISTED TREATMENT (MAT) MARKET 80
5 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT MARKET: REGULATIONS 81
6 MARKET OVERVIEW 84
6.1 DRIVERS 86
6.1.1 THE RISE IN INCIDENCE OF ALCOHOL USE DISORDER AND OPIOID USE DISORDERS 86
6.1.2 THE FUNDING BY THE GOVERNMENT FOR MEDICATION-ASSISTED TREATMENT (MAT) 87
6.1.3 THE RISE IN THE POPULATION RECEIVING MEDICATION-ASSISTED TREATMENT (MAT) AND MEDICATION-ASSISTED AWARENESS PROGRAMMESMEDICATION-ASSISTED TREATMENT (MAT) 87
6.1.4 USE OF REIMBURSEMENT FOR MEDICATION-ASSISTED TREATMENT (MAT) 88
6.2 RESTRAINTS 89
6.2.1 SIDE EFFECTS OF DRUGS USED IN MEDICATION-ASSISTED TREATMENT (MAT) 89
6.2.2 ETHICAL ISSUES RELATED TO USE OF MEDICATION-ASSISTED TREATMENTMEDICATION-ASSISTED TREATMENT (MAT) 89
6.2.3 RISE IN PRODUCT RECALLS 89
6.3 OPPORTUNITIES 90
6.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 90
6.3.2 RISE IN HEALTHCARE EXPENDITURE 91
6.4 CHALLENGES 91
6.4.1 THE LACK OF SKILLED PROFESSIONALS, REQUIRED FOR MEDICATION-ASSISTED TREATMENT 91
6.4.2 STRINGENT REGULATIONS 92
6.4.3 DISCONTINUATION OF MEDICATION-ASSISTED TREATMENT (MAT) 93
7 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE 94
7.1 OVERVIEW 95
7.2 MEDICATION 98
7.2.1 OPIOID DEPENDENCY MEDICATION 99
7.2.1.1 BUPRENORPHINE AND NALOXONE 99
7.2.1.2 BUPRENORPHINE 99
7.2.1.3 METHADONE 99
7.2.1.4 NALTREXONE 100
7.2.2 ALCOHOL USE DISORDER MEDICATIONS 100
7.2.2.1 NALTREXONE 100
7.2.2.2 DISULFIRAM 100
7.2.2.3 ACAMPROSATE 100
7.2.3 OPIOID OVERDOSE PREVENTION MEDICATION 100
7.2.3.1 NALOXONE 101
7.3 THERAPY 101
7.3.1 BEHAVIORAL THERAPY 102
7.3.2 EDUCATIONAL THERAPY 102
7.3.3 COUNSELLING 102
7.3.4 VOCATIONAL THERAPY 102
7.3.5 OTHERS 103
8 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS 104
8.1 OVERVIEW 105
8.2 BUPRENORPHINE AND NALOXONE 108
8.3 NALTREXONE 108
8.4 BUPRENORPHINE 110
8.5 METHADONE 110
8.6 NALOXONE 111
8.7 DISULFIRAM 112
8.8 ACAMPROSATE 113
9 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE 114
9.1 OVERVIEW 115
9.2 GENERICS 118
9.3 BRANDED 118
9.3.1 SUBOXONE 119
9.3.2 VIVITROL 119
9.3.3 BUTRANS 119
9.3.4 ZUBSOLV 120
9.3.5 PROBUPHINE 120
9.3.6 OTHERS 120
10 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM 121
10.1 OVERVIEW 122
10.2 IMMEDIATE RELEASE 125
10.3 EXTENDED RELEASE 125
11 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION 127
11.1 OVERVIEW 128
11.2 ORAL 131
11.2.1 TABLET 132
11.2.2 SUBLINGUAL FILM 132
11.2.3 OTHERS 132
11.3 PARENTERAL 132
11.3.1 SOLUTION 133
11.3.2 SUSPENSION 133
11.4 OTHERS 134
12 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE 135
12.1 OVERVIEW 136
12.2 ADULTS 139
12.3 TEENAGE 139
13 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER 141
13.1 OVERVIEW 142
13.2 REHABILITATION CLINICS 145
13.3 HOSPITALS 145
13.4 SPECIALTY CENTERS 146
13.5 HOMECARE 147
13.6 OTHERS 148
14 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL 149
14.1 OVERVIEW 150
14.2 HOSPITAL PHARMACY 153
14.3 DIRECT TENDER 153
14.4 RETAIL PHARMACY 154
14.5 ONLINE PHARMACY 155
14.6 OTHERS 156
15 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION 157
15.1 ASIA-PACIFIC 158
15.1.1 CHINA 168
15.1.2 JAPAN 173
15.1.3 INDIA 178
15.1.4 AUSTRALIA 183
15.1.5 SOUTH KOREA 188
15.1.6 SINGAPORE 193
15.1.7 MALAYSIA 198
15.1.8 THAILAND 203
15.1.9 INDONESIA 208
15.1.10 PHILIPPINES 213
15.1.11 VIETNAM 218
15.1.12 REST OF ASIA-PACIFIC 223
16 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY LANDSCAPE 224
16.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 224
17 SWOT ANALYSIS 225
18 COMPANY PROFILE 226
18.1 TEVA PHARMACEUTICAL INDUSTRIES LTD. (2021) 226
18.1.1 COMPANY SNAPSHOT 226
18.1.2 REVENUE ANALYSIS 227
18.1.3 COMPANY SHARE ANALYSIS 227
18.1.4 PRODUCT PORTFOLIO 227
18.1.5 RECENT DEVELOPMENTS 228
18.2 INDIVOR PLC (2021) 229
18.2.1 COMPANY SNAPSHOT 229
18.2.2 REVENUE ANALYSIS 229
18.2.3 COMPANY SHARE ANALYSIS 230
18.2.4 PRODUCT PORTFOLIO 230
18.2.5 RECENT DEVELOPMENTS 231
18.3 VIATRIS INC (2021) 232
18.3.1 COMPANY SNAPSHOT 232
18.3.2 REVENUE ANALYSIS 232
18.3.3 COMPANY SHARE ANALYSIS 233
18.3.4 PRODUCT PORTFOLIO 233
18.3.5 RECENT DEVELOPMENTS 233
18.4 SUN PHARMACEUTICAL INDUSTRIES LTD (2021) 234
18.4.1 COMPANY SNAPSHOT 234
18.4.2 REVENUE ANALYSIS 234
18.4.3 COMPANY SHARE ANALYSIS 235
18.4.4 PRODUCT PORTFOLIO 235
18.4.5 RECENT DEVELOPMENTS 235
18.5 ALKERMES (2021) 236
18.5.1 COMPANY SNAPSHOT 236
18.5.2 REVENUE ANALYSIS 236
18.5.3 COMPANY SHARE ANALYSIS 237
18.5.4 PRODUCT PORTFOLIO 237
18.5.5 RECENT DEVELOPMENTS 238
18.6 PURDUE PHARMA L.P. (2021) 239
18.6.1 COMPANY SNAPSHOT 239
18.6.2 PRODUCT PORTFOLIO 239
18.6.3 RECENT DEVELOPMENTS 239
18.7 PFIZER (2021) 240
18.7.1 COMPANY SNAPSHOT 240
18.7.2 REVENUE ANALYSIS 240
18.7.3 PRODUCT PORTFOLIO 241
18.7.4 RECENT DEVELOPMENTS 241
18.8 GLENMARK PHARMACEUTICAL INC (2021) 242
18.8.1 COMPANY SNAPSHOT 242
18.8.2 REVENUE ANALYSIS 242
18.8.3 PRODUCT PORTFOLIO 243
18.8.4 RECENT DEVELOPMENTS 243
18.9 DR. REDDYS LABORATORIES LTD (2021) 244
18.9.1 COMPANY SNAPSHOT 244
18.9.2 REVENUE ANALYSIS 244
18.9.3 PRODUCT PORTFOLIO 245
18.9.4 RECENT DEVELOPMENTS 245
18.10 ALVOGEN (2021) 246
18.10.1 COMPANY SNAPSHOT 246
18.10.2 PRODUCT PORTFOLIO 246
18.10.3 RECENT DEVELOPMENTS 246
18.11 ADAMIS PHARMACEUTICALS CORPORATION (2021) 247
18.11.1 COMPANY SNAPSHOT 247
18.11.2 REVENUE ANALYSIS 247
18.11.3 PRODUCT PORTFOLIO 248
18.11.4 RECENT DEVELOPMENTS 248
18.12 ACCORD HEALTHCARE (A SUBSIDIARY OF INTAS PHARMACEUTICALS) 249
18.12.1 COMPANY SNAPSHOT 249
18.12.2 PRODUCT PORTFOLIO 249
18.12.3 RECENT DEVELOPMENTS 250
18.13 AMNEAL PHARMACEUTICALS LLC (2021) 251
18.13.1 COMPANY SNAPSHOT 251
18.13.2 REVENUE ANALYSIS 251
18.13.3 PRODUCT PORTFOLIO 252
18.13.4 RECENT DEVELOPMENTS 252
18.14 AMERICAN ADDICTION CENTERS (2021) 253
18.14.1 COMPANY SNAPSHOT 253
18.14.2 PRODUCT PORTFOLIO 253
18.14.3 RECENT DEVELOPMENTS 253
18.15 HIKMA PHARMACEUTICALS PLC (2021) 254
18.15.1 COMPANY SNAPSHOT 254
18.15.2 REVENUE ANALYSIS 254
18.15.3 PRODUCT PORTFOLIO 255
18.15.4 RECENT DEVELOPMENTS 255
18.16 LANNETT (2021) 256
18.16.1 COMPANY SNAPSHOT 256
18.16.2 REVENUE ANALYSIS 256
18.16.3 PRODUCT PORTFOLIO 257
18.16.4 RECENT DEVELOPMENT 257
18.17 MALLINCKRODT (2021) 258
18.17.1 COMPANY SNAPSHOT 258
18.17.2 REVENUE ANALYSIS 258
18.17.3 PRODUCT PORTFOLIO 259
18.17.4 RECENT DEVELOPMENT 259
18.18 OREXO US INC (A SUBSIDIARY OF OREXO, INC) (2021) 260
18.18.1 COMPANY SNAPSHOT 260
18.18.2 REVENUE ANALYSIS 260
18.18.3 PRODUCT PORTFOLIO 261
18.18.4 RECENT DEVELOPMENT 261
18.19 PINNACLE TREATMENT CENTERS 262
18.19.1 COMPANY SNAPSHOT 262
18.19.2 PRODUCT PORTFOLIO 262
18.19.3 RECENT DEVELOPMENT 262
18.20 RECOVERY CENTERS OF AMERICA 263
18.20.1 COMPANY SNAPSHOT 263
18.20.2 PRODUCT PORTFOLIO 263
18.20.3 RECENT DEVELOPMENTS 264
18.21 TAJ PHARMACEUTICALS LIMITED 265
18.21.1 COMPANY SNAPSHOT 265
18.21.2 PRODUCT PORTFOLIO 265
18.21.3 RECENT DEVELOPMENTS 265
18.22 TITAN PHARMACEUTICALS (2021) 266
18.22.1 COMPANY SNAPSHOT 266
18.22.2 REVENUE ANALYSIS 266
18.22.3 PRODUCT PORTFOLIO 267
18.22.4 RECENT DEVELOPMENTS 267
18.23 VISTAPHARM, INC (A SUBSIDIARY OF VERTICE PHARMA, LLC. (2021)) 268
18.23.1 COMPANY SNAPSHOT 268
18.23.2 PRODUCT PORTFOLIO 268
18.23.3 RECENT DEVELOPMENTS 268
19 QUESTIONNAIRE 269
20 RELATED REPORTS 273
Segmentation
Short Description
Asia-Pacific Medication-Assisted Treatment (MAT) Market, By Type (Medication and Therapy), Products (Buprenorphine and Naloxone, Naltrexone, Buprenorphine, Methadone, Naloxone, Disulfiram, and Acamprosate), Drug Type (Generics and Branded), Dosage Form (Immediate Release and Extended Release), Route of Administration (Oral, Parenteral, and Others), Population Type (Adults and Teenage), End User (Rehabilitation Clinics, Hospitals, Specialty Centres, Homecare, and Others) Distribution Channel (Hospital Pharmacy, Direct Tender, Retail Pharmacy, Online Pharmacy, and Others), Country (China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific) Industry Trends and Forecast to 2029
Market Definition:
Medication-assisted treatment (MAT) involves using medications, combined with counseling and behavioral therapies, to provide a complete patient approach for treating substance use disorders. MAT is primarily used to treat addiction to opioids such as heroin and prescription pain relievers. MAT aims for proper recovery, which includes improved patient survival, increased treatment retention, reduced illicit response, and increased pregnancy outcomes among women.
The Food and Drug Administration (FDA) approved three clinical drugs: buprenorphine, methadone, and naltrexone. Medication-assisted treatment (MAT) is applied to cure alcohol use disorder, opioid dependency medication, and opioid overdose prevention medication. Alcohol use disorder (AUD) is a medical condition characterized by an impaired ability to stop alcohol use despite adverse social, occupational, or health consequences. Acamprosate, disulfiram, and naltrexone are the most common medications used to treat alcohol use disorder (AUD). The opioid dependency medication, rise in addiction for opioids among patients. Buprenorphine, methadone and naltrexone are used to treat opioid use disorders to short-acting opioids such as heroin, morphine, and codeine, as well as semi-synthetic opioids like oxycodone and hydrocodone. These MAT medications are safe for months, years, or even a lifetime. For opioid overdose prevention medication, naloxone is used to prevent opioid overdose by reversing the toxic effects of the overdose. According to the World Health Organization (WHO) and Substance Abuse and Mental Health Services Administration (SAMHSA), naloxone is one of many essential medications to a functioning health care system.
Market Segmentation:
The Asia-Pacific medication-assisted treatment (MAT) market is categorized into eight segments: type, products, drug type, dosage form, route of administration, population type, end user, and distribution channel.
On the basis of type, the Asia-Pacific medication-assisted treatment (MAT) market is segmented into medication and therapy
On the basis of product, the Asia-Pacific medication-assisted treatment (MAT) market is segmented into buprenorphine and naloxone, naltrexone, buprenorphine, acamprosate, methadone, naloxone, and disulfiram
On the basis of drug type, the Asia-Pacific medication-assisted treatment (MAT) market is segmented into branded and generics
On the basis of dosage form, the Asia-Pacific medication-assisted treatment (MAT) market is segmented into extended-release and immediate-release
On the basis of route of administration, the Asia-Pacific medication-assisted treatment (MAT) market is segmented into oral, parenteral, and others
On the basis of population type, the Asia-Pacific medication-assisted treatment (MAT) market is segmented into children and teenage
On the basis of end user, the Asia-Pacific medication-assisted treatment (MAT) market is segmented into rehabilitation clinics, hospitals, specialty centers, homecare, and others
On the basis of distribution channel, the Asia-Pacific medication-assisted treatment (MAT) market is segmented into direct tender hospital pharmacy, retail pharmacy, online pharmacy, and others
Market Players
Some of the major players operating in the Asia-Pacific medication-assisted treatment (MAT) market are:
Indivior PLC
Sun Pharmaceutical Industries Ltd.
Taj Pharmaceuticals Limited
Hikma Pharmaceuticals PLC
Pfizer Inc.
Glenmark Pharmaceutical Inc.
Viatris Inc.
Alvogen
Accord Healthcare
Teva Pharmaceutical Industries Ltd.
Dr. Reddys Laboratories Ltd.
Amneal Pharmaceuticals LLC. among others
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.